Jerome Benedict Durso, President and CEO at Altimmune, Inc. (ALT), bought 15,000 shares at $2.95 ($44K) on 2026-08-13, disclosed to the SEC on 2026-08-13.
Altimmune CEO Jerome Durso purchased 15,000 shares for $44,250 at $2.95, marking the largest insider purchase in the company's history. This significant buyback by the CEO suggests confidence in the company's pipeline and recent operational progress.
ALT is trading near its 52-week low of $2.57, down 22.99% over the last year and 4.16% in the past five days. The stock is currently 12.28% above its 52-week low but remains 55.28% below its 52-week high of $6.44.
1) Q2 2026 earnings on August 12, 2026, which reported a narrower loss and positive Phase 2 AUD data. 2) Enrollment initiation in the global Phase III PERFORMA trial for pemvidutide in MASH, announced on August 12, 2026. 3) The company has $519 million in cash, supporting operations into 2029.
1) The stock is down 22.99% over the last year, indicating significant bearish sentiment. 2) Short interest represents 26.74% of the float, suggesting high speculative pressure.
Nothing distinguishes this filing.
| Filing → |
| ALT | BUY | 2025-12-22 | $52K | — | Filing → |